oa Preface

It is a pleasure to recognize the present milestone of 12 years of continuous publication for this journal, Current Pharmaceutical Biotechnology (CPB). CPB has grown beyond expectations and is now among the top five in the field of molecular biotechnology in terms of Impact Factor. CPB was originally conceived as a primary review journal in which top areas of research in the fields of pharmaceutical biotechnology and allied disciplines could be covered thematically, much in the same way as a symposium at a scientific meeting is organized. CPB has an electronic version, as do almost all journals, but has resisted the temptation to eliminate print copies - a subscriber can still page through his or her personal copy and browse as they wish. The very best chance of success for CPB is for the journal to be located in all areas of biotechnology and frontier applications creating a new array of opportunities for the pharmaceutical and biomedical sectors. I am proud of all the great work we have accomplished in the last years and equally proud of our approved working plan which is now implemented. It is originally intended to serve a growing market and make our journal more competitive at the Journal Citation Reports. I think that it is important for the contributing authors to know the reasoning behind whatever decision we make and to clearly explain our goals and objectives as a whole. We wish to communicate that we are currently accepting manuscripts in all fields of human endeavour, such as basic sciences like chemistry, physics, mathematics dealing with biological problems, live sciences and clinical studies. Authors are invited to submit manuscripts reporting recent developments in their fields. Given the keen competition for space in CPB, we have published 12-14 issues from Stanford University, Stanford University School of Medicine, Massachusetts Institute of Technology, Johns Hopkins University School of Medicine, St. John's University New York, University of Tokyo, Lilly Research Laboratories, Tokyo University of Pharmacy and Life Sciences, and Karolinska Institutet (Nobel Institute), to name some of the highlights in the field of biotechnology sciences in the period 2010- 2012. We are making changes, but it takes some time to make things happen. Credit must go to the many CPB Guest Editors and Reviewers during the past 12 years who have provided rigor and expertise to each issue. On a personal level, I thank Dr. Matthew Honan of Bentham Science Publishers for the opportunity to be involved with CPB, and to Ms. Ambreen Wasim of the Bentham editorial office for her many efforts from the beginning.....